We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-20.33%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.3B
AUM Growth
-$379M
(-23%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
8.09%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
86
New
8
Increased
9
Reduced
24
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRNA
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
|
+$60.1M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$28.4M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$22.7M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$22.1M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$26.9M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$13.1M |
| 3 |
VERV
Verve Therapeutics
VERV
|
+$11.7M |
| 4 |
Cytokinetics
CYTK
|
+$10.7M |
| 5 |
Zymeworks
ZYME
|
+$9.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORTX
76
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $183K | 0.01% |
25,665
| – | – |
|
77
X4 Pharmaceuticals
XFOR
$460M
| $182K | 0.01% |
3,466
| – | – |
|
|
78
Aclaris Therapeutics
ACRS
$869M
| – | – |
-900,000
| Closed | -$13.1M |
|
79
Aligos Therapeutics
ALGS
$34.9M
| – | – |
-20,850
| Closed | -$6.19M |
|
80
Celldex Therapeutics
CLDX
$3.28B
| – | – |
-100,000
| Closed | -$3.86M |
|
|
CNTB
81
Connect Biopharma Holdings
CNTB
$139M
| – | – |
-200,000
| Closed | -$1.03M |
|
|
MRUS
82
DELISTED
Merus
MRUS
| – | – |
-100,000
| Closed | -$3.18M |
|
83
uniQure
QURE
$3.22B
| – | – |
-50,000
| Closed | -$1.04M |
|
|
84
Zymeworks
ZYME
$1.67B
| – | – |
-600,000
| Closed | -$9.83M |
|
|
SONX
85
DELISTED
Sonendo, Inc.
SONX
| – | – |
-149,200
| Closed | -$859K |
|
|
OTLKW
86
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
| – | – |
-270,698
| Closed | -$32K |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Cormorant Asset Management held 86 positions worth $1.3B, down 23% from $1.68B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Cormorant Asset Management deployed $105M of net new capital in Q1 2022, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.
On the sell side, the largest reduction was Beam Therapeutics, an estimated $26.9M trimmed.
- Cormorant Asset Management's largest Q1 2022 buy was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.
- Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q1 2022, an estimated $28.4M increase.
- Cormorant Asset Management's biggest Q1 2022 reduction was Beam Therapeutics, cutting an estimated $26.9M.
- Cormorant Asset Management fully exited Aclaris Therapeutics in Q1 2022, selling an estimated $13.1M.
- Cormorant Asset Management's ten largest holdings make up 49% of its $1.3B portfolio in Q1 2022.
- Cormorant Asset Management opened 8 new positions and closed 9 in Q1 2022.
- Cormorant Asset Management's portfolio value fell 23% quarter-over-quarter to $1.3B.
Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.